Drug guidance
Recombinant zoster vaccine for the prevention of herpes zoster and post-herpetic neuralgia
Condition
Infections
Vaccines
10 February 2025
Published on 25 Oct 2024
Last Updated on 10 Feb 2025
Guidance Recommendations
The Ministry of Health's Drug Advisory Committee has recommended:
Recombinant varicella zoster virus glycoprotein E 50 mcg/0.5 mL powder and suspension for suspension for injection for the prevention of herpes zoster (HZ) and post-herpetic neuralgia in:
adults 60 years of age or older; and
adults 18 years of age or older at increased risk of HZ due to immunodeficiency or immunosuppression caused by known disease or therapy.
Subsidy status
Recombinant varicella zoster virus glycoprotein E 50 mcg/0.5 mL powder and suspension for suspension for injection is recommended for inclusion on the MOH Subsidised Vaccine List (SVL) for the abovementioned indication from September 2025.